Scientific breakthrough paves the way for the next generation of pain relief

Auxesis Pharma first in the world with liquid acetylsalicylic acid

After nearly a decade of research, Swedish pharmaceutical company Auxesis Pharma has achieved a scientific breakthrough that could change how pain is treated. The company is the first in the world to stabilize acetylsalicylic acid (ASA) in liquid form, something long considered technically impossible.

The new formulation also meets authorities’ requirement of at least two years of shelf life — a decisive step toward a finished medicine that can reach patients worldwide.

“Acetylsalicylic acid in tablet form has been used for more than a hundred years. But stabilizing it in liquid form is something no one has managed to do before now. This is a product people around the world are looking for.”

Heading toward clinical studies

The breakthrough means the company is now moving into the next development phase. The formulation is expected to be submitted to the Swedish Medical Products Agency for approval in the first quarter of 2026, and clinical studies are planned to begin in the first half of the same year. Work continues to optimize the formulation and prepare the studies.

During autumn 2025, efforts continue at full pace to refine the formulation and prepare upcoming trials. The goal is a market launch in 2027–2028, first in Sweden and then internationally.

A new way to treat pain

Stabilizing ASA in liquid form opens the door to a completely new type of pain-relief medicine that can be applied directly to the skin. The product may have broad use — from insect bites, sunburn and muscle pain to more complex pain and skin conditions.

In parallel, the company is also developing a veterinary-health variant, where the demand for effective, antibiotic-free options is rapidly growing.

Broad potential — from pain to preventive medicine

Acetylsalicylic acid is known for its pain-relieving effect, but is also used to prevent blood clots and reduce the risk of heart attack and stroke. The new liquid form opens possibilities for several new applications:

• Faster effect — Liquid form may enable faster absorption and therefore faster pain reduction.

• Easier for certain patient groups — Children, older adults and people with swallowing difficulties may find it easier to take the medicine.

• Combination products — The formulation enables new combinations with other active substances for optimized treatment.

Manufacturing in Östersund and research collaboration

Auxesis Pharma is currently building a production facility in Östersund, which will be a key part of the company’s long-term commitment to Swedish manufacturing. At the same time, the company collaborates with researchers in Lund to further develop the technology.

Once manufacturing is up and running, the plan is to launch in Sweden, followed by expansion into other European countries and global markets.

“This breakthrough shows that we are fully on track with our development plan. We have finally reached the point where we can say we have a product that works.”

A bright future for Swedish pharmaceutical innovation

The breakthrough places Auxesis Pharma in a unique position in the global pharmaceutical market. The company has worked intensively on research and development for more than ten years. Now it looks ahead to a new phase of regulatory approvals, clinical studies and a potential launch.